Georgina V. Long

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  

Georgina V. Long
Jun 11, 2025, 22:22 | Insight
Elizabeth McKenna Shared an Article on Federated Deep Learning Enables Cancer Subtyping by Proteomics
Elizabeth McKenna, Executive Editor of Cancer Discovery, shared a post on X: "Now online in…
Jun 10, 2025, 10:03 | Science
Mario Mandalà: The Impact of SRT in Melanoma Patients with Brain Metastases Receiving Combo Immunotherapy
Mario Mandalà, Director of Medical Oncology at S.M. Misericordia Hospital and an Associate Professor of Medical…
Jun 10, 2025, 05:11 | Insight
Yan Leyfman: Are Immune Checkpoint Inhibitors Safe for Patients with Neurologic Autoimmune Disorders
Yan Leyfman, Co-founder and Executive Director of MedNews Week, posted on LinkedIn: "Are Immune Checkpoint…
Jun 9, 2025, 15:41 | Science
Rafeh Naqash Shares Article on Immune Checkpoint Inhibitors For Patients With Autoimmune Neurologic Disorders
Rafeh Naqash, Assistant Professor at OU Health Stephenson Cancer Center and 2025 Yvonne ‘Mentorship’ Award…
Jun 9, 2025, 07:12 | Blog
Yan Leyfman: Are Immune Checkpoint Inhibitors Safe for Patients with Neurologic Autoimmune Disorders?
Yan Leyfman, Co-founder and Executive Director of MedNews Week, posted on X: "Are Immune Checkpoint…
Jan 18, 2025, 14:50 | Blog
Don’t miss the 11th World Congress of Melanoma and 21st EADO Congress
Marco Donia shared a post by Melanoma World Society, on LinkedIn: "Neoadjuvant or Perioperative Immunotherapy:…
Jan 2, 2025, 15:54 | Blog
Yakup Ergün: Final Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a post on X: "Final, 10-Year…
Dec 24, 2024, 17:32 | Blog
Three-Year Overall Survival with Nivolumab + Relatlimab rela-nivo in Advanced Melanoma
Marco Donia shared on LinkedIn: "Three-Year Overall Survival with Nivolumab + Relatlimab (rela-nivo) in Advanced…
Dec 17, 2024, 06:25 | Opinion
Andrea Boutros: RELATIVITY-047 trial showing sustained benefit of Nivolumab plus Ipilimumab in advanced melanoma
Andrea Boutros, Medical Doctor and Oncology Resident at San Martino Polyclinic Hospital, shared on X:…
Sep 24, 2024, 12:30 | Societies
11 ESMO24 presentations published on NEJM
At the 2024 ESMO Congress, 11 articles were presented that were published in NEJM, highlighting…
Sep 1, 2024, 10:46 | Insight
Article of the day, September 1st, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 30, 2024, 10:39 | Insight
Article of the day, August 30th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 29, 2024, 11:25 | Insight
Article of the day, August 29th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 21, 2024, 08:20 | Insight
5 articles suggested by Vivek Subbiah
Vivek Subbiah shared a few must-reads paper on X: 1. Dose selection of novel anticancer…
Jun 25, 2024, 14:38 | Insight
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results       …
Jun 21, 2024, 18:05 | Blog
Nature Reviews Cancer - Exploiting temporal aspects of cancer immunotherapy
Giannis Mountzios, Medical Oncologist at the Department of Medical Oncology in the Air Force General Hospital,…
Jun 5, 2024, 04:04 | Drugs
Jon Wigginton: Very exciting phase 3 data regarding stage 3 melanoma
Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “NEJM…
All: 17 Posts: 1 - 100
Special Coverage